Type 10 collagen alpha 1 (COL10A1) is a short-chain collagen of cartilage synthesized by chondrocytes during the growth of long bones. COL10A1 mutations, which frequently result in COL10A1 haploinsufficiency, have been identified in patients with Schmid metaphyseal chondrodysplasia (SMCD), a cartilage disorder characterized by short-limbed short stature and bowed legs. Similarities between SMCD and short stature in various dog breeds suggested COL10A1 as a candidate for canine skeletal dysplasia. We report the sequencing of the exons and promoter region of the COL10A1 gene in dog breeds fixed for a specific type of skeletal dysplasia known as chondrodysplasia, breeds that segregate the skeletal dysplasia phenotype, and control dogs of normal stature. Thirteen single nucleotide polymorphisms (SNPs), one insertion, and two deletions, one of which introduces a premature stop codon and likely results in nonsense-mediated decay and the degradation of the mutant allele product, were identified in the coding region. There appear to be no causal relationships between the polymorphisms identified in this study and short stature in dogs. Although COL10A1 haploinsufficiency is an important cause of SMCD in humans, it does not seem to be responsible for the skeletal dysplasia phenotype in these dog breeds. In addition, homozygosity for the nonsense allele does not result in the observed canine skeletal dysplasia phenotype.
Introduction
Type 10 collagen alpha 1 (COL10A1) is a short-chain collagen of cartilage synthesized by chondrocytes during the growth of long bones (Schmid et al. 1985) . It is a homotrimer with non-triple-helical regions flanking the central short triple-helical domain (Yamaguchi et al. 1991) . The coding region of this gene in humans is represented by the last two of three exons. Exon 2 encodes the amino-terminal noncollagenous domain (NC2) and exon 3 encodes part of NC2, the collagenous domain, and the carboxy-terminal noncollagenous domain (NC1) (Thomas et al. 1991) .
The COL10A1 gene has been associated with specific forms of skeletal dysplasia in humans. Skeletal dysplasias are a heterogeneous group of inherited defects of endochondral ossification, the developmental process by which cartilage is converted to bone (Mortier 2001) . Approximately 200 different skeletal dysplasias have been identified in humans, ranging in clinical severity from mildly affected short stature to lethal forms (Tuysuz 2004 ). One such type of skeletal dysplasia, chondrodysplasia, which affects cartilage and the growth of long bones, results in various forms of disproportionate short stature, or dwarfism. Diagnoses of specific forms of chondrodysplasia are based mainly on radiographs, but the identification of some of the underlying genetic defects have recently enabled biochemical and DNA analyses to be used to confirm radiographic evaluations (Mortier 2001 ).
Schmid metaphyseal chondrodysplasia (SMCD), a specific type of chondrodysplasia, is known to be caused by mutations in the COL10A1 gene (Warman et al. 1993) . SMCD is an autosomal dominant cartilage disorder (Reichenberger et al. 1992 ) characterized by short-limbed short stature, bowed legs, and a waddling gait (Sawai et al. 1998 ). The majority of reported mutations associated with SMCD are in the region of the gene that encodes the NC1 domain (Bateman et al. 2005) . It has been shown that COL10A1 haploinsufficiency is a significant molecular cause of SMCD, specifically in patients with nonsense or frameshift mutations (Bateman et al. 2003 ; Chan et al. 1998) .
Similarities between SMCD and skeletal dysplasia in various dog breeds suggested COL10A1 as a candidate gene for the canine phenotype. In both species, asynchronous growth of the radius and ulna result in curvature of the radius and thickening of the bones of the limbs, resulting in the characteristic short-limbed, bow-legged phenotype. Splaying of the metaphyses is also seen in both humans and dogs. SMCD, like canine skeletal dysplasia, is a comparatively mild short-stature phenotype with no other associated health problems.
Canine skeletal dysplasias, including chondrodysplasia, are primarily diagnosed by radiograph. Breeds such as Basset Hounds, in which there is no segregation of the phenotype, are considered to be fixed for chondrodysplasia (Stockard 1941 ). These breeds often experience complications that require treatment or surgery, such as intervertebral disk disease (IVDD), that are directly linked to the chondrodysplastic phenotype (Verheijen and Bouw 1982) . Crosses between breeds fixed for chondrodysplasia and dogs of normal stature have demonstrated an autosomal dominant mode of inheritance in these breeds (Stockard 1941) .
A condition similar to chondrodysplasia has been observed to segregate in Chesapeake Bay Retrievers, Newfoundlands, and Nova Scotia Duck Tolling Retrievers. The disorder is also characterized by short stature and bowed, thickened front legs but appears to be less severe than chondrodysplasia (Fig. 1) . The mode of inheritance has not been determined in these breeds. Since this condition is not known to be allelic to canine chondrodysplasia, we refer to it as skeletal dysplasia. Variation in phenotypic expression complicates the diagnosis in the aforementioned breeds and mildly affected individuals are often mistakenly classified as normal. This is important since these individuals appear capable of producing severely affected offspring. In severe cases, the condition can be so debilitating that surgery or euthanasia is required. The current methods of diagnosis by clinical and radiologic analysis are effective for diagnosing severe cases, but they are often inconsistent in cases with milder presentations. Understanding the genetic basis of canine skeletal dysplasias would enable more accurate diagnosis and facilitate genetic counseling to help breeders avoid producing affected dogs.
We report the sequencing of the three COL10A1 exons as well as 350 bp of the promoter region in four dog breeds that are fixed for chondrodysplasia, three breeds that segregate the skeletal dysplasia phenotype, and three control dogs of normal stature. Because of the structure of dog breeds, diseases seen within breeds are identical by descent, making it possible to identify the molecular cause for a particular canine disease by evaluating affected individuals within the breed (Ostrander and Kruglyak 2000) . Thirteen single nucleotide polymorphisms (SNPs), one insertion, and two deletions were identified in the coding region of the COL10A1 gene. There appear to be no causal relationships between these polymorphisms and skeletal dysplasia in these breeds. One of the identified deletions introduces a premature stop codon, which likely results in nonsense-mediated decay and the degradation of the mutant allele product. This deletion was seen in dogs of several different breeds in the heterozygous and the homozygous state and does not correlate with the skeletal dysplasia phenotype under investigation.
Materials and methods
DNA isolation. Blood samples were acquired from patients of the University of California at Davis Veterinary Medical Teaching Hospital. Genomic DNA was isolated using the QiaAmp DNA Blood Mini Kit (Qiagen, Valencia, CA). Additional DNA samples, extracted primarily from buccal swabs, were acquired from the Veterinary Genetics Laboratory at the University of California at Davis. Buccal swab samples from Nova Scotia Duck Tolling Retrievers and Chesapeake Bay Retrievers were obtained from breeders and owners. DNA was extracted from buccal swabs by adding 500 ll of 50 mM NaOH to each swab, heating the sample at 96°C for 5 min and adding 75 ll of 1 M Tris.
For breeds that segregate the skeletal dysplasia phenotype, samples were obtained from two affected individuals. The affected Newfoundlands that were tested are full siblings, as are the Chesapeake Bay Retrievers. The two Nova Scotia Duck Tolling Retrievers are a severely affected individual and its affected dam.
Primer development. Canine sequence for exons 2 and 3 was obtained by a cross-species comparison using a discontiguous MegaBLAST of human COL10A1 to the canine trace archives (http:// www.ncbi.nih.gov/genome/guide/dog/). Primers were designed across exon/intron boundaries and are listed in Table 1 .
Promoter and exon 1 sequences were obtained from the UCSC genome browser (http://www. genome.ucsc.edu/) by performing a BLAT search with human COL10A1 promoter and exon 1 sequence. Boundaries for canine exon 1 were determined based on homology with human exon 1 sequence. Primers pF1 and pR1 were used for PCR and sequencing of the promoter region. Primers pF2 and pR2 were used to provide additional sequence in areas that did not provide adequate sequence with the PCR primers ( Table 1) . Overlapping sequence fragments from these primers were assembled using the ContigExpress function of Vector NTI (Informax, Frederick, MD).
PCR. Polymerase chain reaction (PCR) was performed on a GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA) with 1 ll DNA, 2.5 mM dNTP, 0.5 U AmpliTaq Gold Polymerase (Applied Biosystems), 1 ll 10· Buffer II with 1.5 mM MgCl 2 , and water to 20 ll. Amplification parameters were: 95°C for 12 min, 35 cycles of 94°C for 30 sec, 60°C for 60 sec, and 72°C for 2 min, with a final extension of 72°C for 20 min. Products were purified using the QIAquick PCR Purification Kit (Qiagen).
Sequencing. Purified PCR products were sequenced with the ABI Prism BIGDye Terminator Cycle Sequencing Kit (v3.1) on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems) and visualized using Chromas2 (Technelysium, Tewantin, Queensland, Australia). Sequences were obtained from breeds fixed for chondrodysplasia: Basset Hound, Dachshund, Pekinese, Pembroke Welsh Corgi, three individuals affected with skeletal dysplasia: Chesapeake Bay Retriever, Newfoundland, and Nova Scotia Duck Tolling Retriever, and two controls of normal stature: a Dalmatian and a wolf (Canis lupus). The available canine genome sequence (Boxer) was used as an additional normal control. Dalmatian sequences were submitted to GenBank (accession Nos. DQ286968, AY903955, and AY903956). Sequence alignment was performed using VectorNTI (Informax). A.E. YOUNG ET AL.: COL10A1 DELETIONS DO NOT CAUSE CANINE SKELETAL CHANGES Cloning. PCR products that gave unclear results by direct sequencing were cloned using the TOPO TA Cloning Kit (pCR Topo 2.1-TOPO vector) (Invitrogen, Carlsbad, CA). Sequencing proceeded as described above.
Genotyping. Genotyping of polymorphisms in samples from additional breeds was performed on an ABI Prism 3100 Genetic Analyzer using GeneScan 400 HD Rox size standard (Applied Biosystems). Product sizes were analyzed using STRand software (Toonen 2001) .
Results
The three exons and 350 bp of the promoter region of the COL10A1 gene were sequenced in nine individuals from seven breeds with short stature and two normal-legged controls. No differences were identified in exon 1 or the promoter region between breeds. A 3-bp difference in exon 2 was characterized as an insertion based on its absence in the wolf sequence, which was defined as wild type. The insertion results in the addition of a proline in the NC2 domain of the protein. This polymorphism was heterozygous in the Dalmatian control and the insertion was homozygous in the Boxer. Results for the affected breeds are presented in Table 2 . Fluorescently labeled primers were designed (Table 1 : Ex2gF and Ex2gR) to assay this polymorphism in additional samples. A PCR product size of 144 bp was associated with ''wild-type'' sequence and 147 bp signified sequence that contained the insertion.
A total of 13 SNPs were identified in exon 3. Six of these SNPs did not cause an amino acid change. The remaining SNPs were sequenced in a second Basset Hound to determine if they warranted further testing. It was assumed that since Basset Hounds are fixed for the skeletal dysplasia phenotype, all individuals would be homozygous for a causative mutation. SNPs 229, 241, 430, 1103, and 1285 were found to be heterozygous in the second Basset Hound and were not tested further. The SNP at base pair 440 was homozygous in the Basset Hound and the Dachshund that were sequenced (Table 2 ) and appeared to cause a significant amino acid change (arginine to histidine). This SNP was further assayed in a panel composed of individuals from 24 different breeds by amplifying the product with primers Ex3F2 and Ex3R2 and then digesting the product with the restriction enzyme BsaHI. The G allele has one BsaHI site, giving bands of 228 and 739 bp. The A allele has no BsaHI restriction sites (product size = 967 bp). The SNP at base pair 838 was homozygous in the second Basset Hound that was sequenced and appears to cause a significant amino acid change (proline to serine). The affected amino acid is also highly conserved between other mammalian COL10A1 protein sequences. This SNP was amplified with the same primers and assayed in the 24 breed panel with a SmaI restriction digestion. The T allele is cut at two sites yielding bands of 570, 280, and 122 bp. The C allele is digested at three sites giving bands of 340, 280, 230, and 122 bp. These SNPs were assayed in an additional affected individual from each of the breeds that segregate skeletal dysplasia ( Table 3 ). As shown in Table 2 , SNP 1285 was homozygous in the Chesapeake Bay Retriever. A second severely affected Chesapeake Bay Retriever was sequenced and was homozygous for the G allele present in the control dogs. These results indicated that this SNP does not cause skeletal dysplasia and it was not tested further. A 9-bp deletion at the end of the triple-helix region was also identified in exon 3 ( Table 2 ). This results in the deletion of a glycine and two prolines, amino acids 513À515 of the protein. Fluorescently labeled primers were designed to assay this polymorphism in samples from additional breeds (Table 1: Ex3gF and Ex3gR). The PCR product size was 200 bp; a PCR product size of 191 bp signified sequence that contained the 9-bp deletion. Upon analysis it was discovered that some individuals have a 4-bp deletion in this region (PCR product size = 196 bp) which causes a frameshift at codon 514 resulting in 13 novel amino acids and the subsequent introduction of a premature stop codon at amino acid 526 of the protein. The premature stop codon would result in the predicted deletion of 150 of the 158 amino acids in the NC1 domain (Fig. 2) .
To determine how frequently these deletions were found in other breeds, a total of 647 dogs, rep- resenting 149 different breeds, were genotyped. The full-length allele was seen most often, with an allele frequency of 0.708. The 9-bp deletion had an allele frequency of 0.243 and the 4-bp deletion had an allele frequency of 0.049. The 4-bp deletion was found as a heterozygote with either the full-length allele or the 9-bp deletion in the following breeds: Bichon Frise, Catahoula Leopard Dog, Cavalier King Charles Spaniel, Chesapeake Bay Retriever, Chihuahua, Dachshund, English Cocker Spaniel, Labrador Retriever, Newfoundland, Nova Scotia Duck Tolling Retriever, Shih Tzu, Spinone Italiano, Toy Fox Terrier, and Vizsla. Homozygotes for the 4-bp deletion were identified in Labrador Retrievers and Shih Tzus. The 4-bp deletion allele was sequenced in Labrador Retrievers, Shih Tzus, Chesapeake Bay Retrievers, Nova Scotia Duck Tolling Retrievers, and Newfoundlands and was determined to be the same allele in these breeds. Primary sequence data for the deletions is presented in Supplementary  Fig. 1 .
Discussion
More than 30 COL10A1 mutations, including missense mutations and mutations that introduce premature stop codons (nonsense and frameshift mutations), have been linked to SMCD in humans (Bateman et al. 2005) . Almost all of the known COL10A1 mutations in humans have been identified in the critical NC1 trimerization domain. The actual mechanism by which these mutations cause SMCD has been a point of some debate. One possibility is that missense mutations could exert a dominant negative effect (Gregory et . Transgenic mice with a dominant negative COL10A1 mutation exhibit dwarfism characteristics such as short stature and bowed legs. Perinatal lethality at three weeks after birth was revealed in some lines of transgenic mice and variable dwarfism, ranging from severe to very mild, was seen in other lines (Jacenko et al. 1993 ).
Research in humans and mice has shown that mutant transcripts containing premature stop codons can be degraded by way of nonsense-mediated decay in cartilage cells, leading to COL10A1 haploinsufficiency (Bateman et al. 2003; Chan et al. 1998) . Most recent studies support the theory that COL10A1 haploinsufficiency, specifically in patients with nonsense or frameshift mutations, is the most common cause of SMCD (Bateman et al. 2005) .
Despite the identification of SNPs and insertion/ deletions, the results of sequencing the exons and promoter region of the COL10A1 gene in dogs did not identify any mutations that appear to cause canine skeletal dysplasia in the breeds studied. The 4-and 9-bp deletions in the NC1 domain, as well as the two SNPs identified in exon 3 that appear to cause significant amino acid changes, were seen in the homozygous and heterozygous states in affected dogs and in additional dogs of normal stature. The 3-bp insertion polymorphism seen in exon 2 is present in the homozygous and heterozygous states in the controls (Table 2) . Based on the fact that almost all human COL10A1 mutations are in the NC1 domain, it was assumed that mutations in this region would be significant in dogs as well. Only one significant sequence change, the 9-bp/4-bp deletion, was seen in the canine NC1 domain. In addition, most of the known NC1 mutations in humans are missense mutations that result in misfolding of the It is interesting to note that, although COL10A1 haploinsufficiency is extremely significant in human chondrodysplasia, this study shows that it does not appear to be responsible for canine skeletal dysplasia. The 4-bp deletion identified in exon 3 of the canine COL10A1 gene would result in a protein that is missing 150 residues of the NC1 domain. In humans, the mutant allele product would be degraded and the truncated protein would not be made. It is reasonable to assume that the same result would be seen in dogs. In humans, this type of deletion would result in COL10A1 haploinsufficiency and manifest itself in the form of SMCD. This deletion was observed at a low frequency in the heterozygous state in affected and unaffected dogs, suggesting that COL10A1 haploinsufficiency does not cause canine skeletal dysplasia.
Initially, no dogs homozygous for the 4-bp deletion were identified, leading to the hypothesis that this deletion was homozygous lethal. Upon further testing, seven homozygotes were found, two Labrador Retrievers and five Shih Tzus. Although it is not possible to definitively rule out that these dogs may have a very mild skeletal phenotype, they do not have the striking skeletal dysplasia phenotype that was under investigation. The promoter region was sequenced to verify that there were no mutations that might alter transcription and none were identified. Unfortunately, growth plates from affected dogs are not available to investigate potential expression differences between the full-length allele and the 4-bp deletion allele. Therefore, it cannot be conclusively determined that the mutant protein is not functional. Research in humans and mice has concluded that the NC1 domain is critical to COL10A1 function so it is reasonable to assume that it is important in dogs as well. Perhaps the deletion confers a phenotype that is not associated with skeletal changes.
The breeds in which the 4-bp deletion was identified are not necessarily closely related. This indicates that the deletion may be an older mutation or that it has arisen more than once. Four wolves and one wolf hybrid were genotyped in the course of this study and all had the full-length COL10A1 allele. Because of the low allele frequency of this deletion in dogs and the number of wolves tested, it cannot be concluded that it does not exist in wolves or other canids.
This study does not exclude COL10A1 as the gene responsible for skeletal dysplasia because intronic sequences were not explored. However, the presence of multiple heterozygous SNPs in the affected breeds, as well as pairs of affected samples from breeds that segregate skeletal dysplasia, makes it unlikely that mutations in noncoding regions cause the phenotype. No mutations were found in the exons or promoter region of COL10A1 that are linked to or cause skeletal dysplasia in these dog breeds. 
